Point72 Asset Management
SCMP

Point72 Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Point72 Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,863,435
Closed -$22M – 1210
2017
Q3 		$22M Buy
+1,863,435
New +$20.9M 0.1% 248
2017
Q1 		– Sell
-133,100
Closed -$1.8M – 1038
2016
Q4 		$1.8M Sell
133,100
-38,500
-22% -$537K 0.01% 573
2016
Q3 		$2.11M Buy
+171,600
New +$2.02M 0.01% 560

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Point72 Asset Management's SCMP Position: Q4 2017 in Review

Point72 Asset Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 1,863,435 shares — an estimated $22M sold.

Point72 Asset Management first reported a position in SCMP in Q3 2016 and held it in 3 quarters. The position peaked at $22M in Q3 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

  • Point72 Asset Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Point72 Asset Management sold 1,863,435 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $22M.
  • Point72 Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • Point72 Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $22M in Q3 2017.
  • 188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Point72 Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.